Surrozen, Inc. provided a business update on its focus on severe eye diseases and progress in its ophthalmology pipeline. Key third quarter events include presenting Next Generation Wnt Therapeutics in Retinal Diseases and strengthening leadership roles. Financially, the company reported a net loss of $71.6 million for the quarter, with cash and cash equivalents at $81.3 million as of September 30, 2025.

The company’s ophthalmology pipeline includes lead candidates SZN-8141 and SZN-8143 for retinal diseases. SZN-8141 combines Fzd4 agonism and VEGF antagonism, potentially offering benefits over single agents for DME and wet AMD. SZN-8143 combines Fzd4 agonism, VEGF antagonism, and IL-6 antagonism, showing potential for treating multiple retinal vascular diseases.

Surrozen’s SZN-413, a bi-specific antibody targeting Fzd4-mediated Wnt signaling, is being developed for retinal diseases through a partnership with Boehringer Ingelheim. Under the agreement, Boehringer Ingelheim pays Surrozen $12.5 million upfront and up to $586.5 million in milestone payments, plus royalties on sales. Data shows SZN-413’s ability to stimulate Wnt signaling for retinal vessel regrowth.

Surrozen is a biotechnology company specializing in Wnt-based therapeutics for tissue repair and regeneration, particularly in ophthalmology. The company aims to deliver durable therapies that can transform patient outcomes. Forward-looking statements caution that actual results may differ due to various factors, including research progress and global economic conditions. The company’s unaudited financial statements show a net loss of $71.6 million for the quarter, with assets totaling $94,046 million as of September 30, 2025.

Read more at GlobeNewswire: Surrozen Reports Third Quarter 2025 Financial Results and